Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9
- Estrogen Replacement Therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 385608
Fablyn means lasofoxifene tartrate. Fablyn (lasofoxifene tartrate) is a selective estrogen receptor modulator (SERM) intended for the treatment of osteoporosis in postmenopausal women.
IPSCIO Record ID: 3014
IPSCIO Record ID: 385607
Pradefovir is a prodrug that targets adefovir to the liver for the treatment of hepatitis B.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection.
IPSCIO Record ID: 1011
IPSCIO Record ID: 314345
Licensee shall have the right to sublicense the rights granted to it under this Agreement to any third party or parties.
is dramatically decreased. Subsequently elderly women develop commonly climacteric symptoms including hot flushes, sweating, insomnia, depression, headache, vaginal dryness, cardiovascular symptoms, urinary incontinence, swelling feeling, breast tenderness and fatigue. In long-term estrogen deficiency induces cardiovascular disorders and osteoporosis which increase the risk of bone fractures and hospitalizations.
Patents shall mean granted US patent No 6,576,645 and its divisional allowed US patent application No 10/408,303, both titled 'Triphenylalkene derivatives and their use as selective estrogen receptor modulators' and any corresponding issued patent or filed patent application based on the inventions described in US patent 6,576,645 or the US patent application 10/408,303 that are filed or granted in any country of the world including any corresponding patent applications filed in any country or territory, or based on any divisionals, continuations, continuations-in-part, reissues, re-examinations, and extensions of any of the foregoing (including any 'patent term restoration' period or supplementary protection certificate granted under applicable laws in a given country).
Patent #6,576,645 – Triphenylalkene derivatives and their use as selective estrogen receptor modulators
Product(s) shall mean any pharmaceutical product containing i) any of the compounds identified in the Invention as its active ingredient alone or in combination of other active ingredients; ii) any molecule that has similar pharmacological properties with such compounds and falls within the claims of the Patents.
Licensee a pharmaceutical company focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas relating to the treatment of hormone deficiencies that result from aging in men and women.
IPSCIO Record ID: 356972
Licensed Products means the Daily Product and any Product Patch with a New Dosing Duration.
Daily Product means a Product Patch which is intended to deliver PTH formulations to a patient one time each day.
New Dosing Duration shall be any dosing duration, other than once daily, with respect to a Product Patch or Licensed Product. For example, if a Licensed Product has an administration once daily, then a once weekly administration would be a New Dosing Duration.
Pen means the pre-filled cartridge pen device currently marketed by Licensee to administer via injection once daily formulations of the Licenseeâ€™s recombinant human PTH analog (1-34) rhPTH (1-34) or manufactured by Licensee to administer a placebo.
Product Patch means a micro-projection array which pierces through the outmost, the stratum corneum, layer of the skin and either in which the micro-projections are coated with a formulation containing PTH as an active pharmaceutical ingredient, to deliver such active pharmaceutical ingredient into or through the skin, in a passive, diffusion-mediated manner, or to form pathways for diffusion-mediated delivery of PTH as an active pharmaceutical ingredient into or through the skin, in each inclusive of an applicator device, API, patch and packaging. For purposes of clarity, the Product Patch shall include all dosage and timed release formulations of PTH.
Licensee currently markets ForteoÂ®, a once-daily formulation of Licenseeâ€™s recombinant human PTH analog (1-34) rhPTH(1-34) administered by subcutaneous injection and approved in the United States for the treatment of severe osteoporosis.
FORTEO is a prescription medicine used to treat postmenopausal women who have osteoporosis who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments. FORTEO can lessen the chance of broken bones (fractures) in the spine and other bones in postmenopausal women with osteoporosis. FORTEO is used to increase the bone mass in men with primary or hypogonadal osteoporosis who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments. FORTEO is used to treat both men and women with osteoporosis due to use of glucocorticoid medicines, such as prednisone, for several months, who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments.
IPSCIO Record ID: 4723
IPSCIO Record ID: 60407
IPSCIO Record ID: 266834
— all of its rights, title and interest in and to the Invention to the intent that the grant of any Patents thereon shall be in the name and vest of Licensee; together with all rights and powers arising or accrued therefrom including, but not limited to, the right to sue for damages and other remedies in respect of any infringement of such rights or other acts within the scope of any claims accompanying the Patent rights.
— the right to apply for, prosecute and obtain Patent or similar protection throughout the world in respect of the Invention including, but not limited to the right to claim priority from any filed patent application to the intent that the grant of any Patents or similar protection shall be in the name of Licensee.
— However, the University shall be entitled, free of any charge and without any compensation, to perpetually use the Invention, whether patented or not, for their further academic, non-commercial research and for teaching purposes. Right to commercially use and exploit any new invention which is related to the treatment or prevention of lower urinary tract symptoms or pelvic pain and which is directly and solely arising out of exercising such right shall be first offered to Licensee.
The patent is titled Method for the Treatment or Prevention of Lower Urinary Tract Symptoms or Pelvic Pain.